Kalaris Therapeutics annual free cash flow
2019
2020
2021
2025
Kalaris Therapeutics Free Cash Flow (FCF) History (KLRS)
Kalaris Therapeutics reported −$38.6M in free cash flow for fiscal 2025.
View full Kalaris Therapeutics company overviewKalaris Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$38.6M | — | — | — |
| 2021 | 2021-12-31 | −$106.3M | −$45.3M | — | — |
| 2020 | 2020-12-31 | −$61.0M | −$40.6M | — | — |
| 2019 | 2019-12-31 | −$20.5M | — | — | −12420.61% |
Kalaris Therapeutics quarterly free cash flow
Q3.19
Q1.21
Q2.21
Q3.21
Q4.21
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$7.1M | — | — | — |
| Q4 2021 | 2021-12-31 | −$28.4M | — | — | — |
| Q3 2021 | 2021-09-30 | −$36.5M | — | — | — |
| Q2 2021 | 2021-06-30 | −$23.2M | — | — | — |
| Q1 2021 | 2021-03-31 | −$19.0M | — | — | — |
| Q3 2019 | 2019-09-30 | −$6.4M | — | — | — |
Kalaris Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$61.0M to −$38.6M, a net increase of $22.5M. Kalaris Therapeutics's latest reported quarter, Q4 2025, generated −$7.1M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Kalaris Therapeutics source filings ↗